carcinomas

Related by string. carcinoma * * Renal Cell Carcinoma RCC . transitional cell carcinoma . basal cell carcinoma BCC . superficial basal cell carcinoma . operable basal cell carcinoma . renal cell carcinoma . hepatocellular carcinoma HCC . squamous cell carcinoma SCC . infiltrating ductal carcinoma . DCIS ductal carcinoma . nasopharyngeal carcinoma NPC . basal cell carcinoma *

Related by context. All words. (Click for frequent words.) 76 carcinoma 70 metastases 70 neoplasms 70 papillary 69 neoplasm 68 GISTs 68 squamous cell carcinomas 68 lymph node metastases 68 breast carcinomas 68 adenocarcinomas 67 endometrial cancers 67 neoplasia 67 malignancies 67 epithelial tumors 67 bladder cancers 66 lymph node metastasis 66 urothelial carcinoma 66 paragangliomas 66 squamous cell carcinoma 66 neuroendocrine tumors 66 pancreatic cancers 66 PCa 66 lung carcinomas 66 renal tumors 66 pheochromocytoma 66 gastric cancers 66 pancreatic adenocarcinoma 66 hamartomas 66 invasive carcinoma 65 metastatic 65 distant metastasis 65 sarcomas 65 pleomorphic 65 breast carcinoma 65 adenocarcinoma 65 cell carcinoma 65 metastatic lesions 65 epithelial cancers 65 histologically 65 osteosarcomas 65 squamous 65 cervical lymph nodes 64 squamous cell 64 meningiomas 64 premalignant 64 uveal melanoma 64 carcinoma HNSCC 64 malignancy 64 malignant lesions 64 ovarian carcinoma 64 cell carcinomas 64 hyperplastic 64 lymphomas 64 prostate cancer CaP 64 cancers 64 colorectal carcinoma 64 renal cell carcinomas 64 Metastatic 64 squamous cell carcinoma SCC 64 distant metastases 64 prostate carcinoma 64 neoplasias 64 papillary renal cell carcinoma 64 transitional cell carcinoma 64 hepatocellular carcinoma HCC 63 pulmonary metastases 63 metastatic disease 63 neoplastic 63 mucinous 63 lobular carcinoma 63 adenomatous polyps 63 gastric adenocarcinoma 63 leiomyomas 63 advanced adenomas 63 situ LCIS 63 anaplastic 63 MALT lymphoma 63 skeletal metastases 63 tumoral 63 lung metastases 63 precursor lesions 63 axillary lymph nodes 63 intestinal metaplasia 63 astrocytomas 63 mesotheliomas 63 pancreatic gastric 63 grade cervical intraepithelial 63 tumors 63 carcinoid tumor 63 chondrosarcoma 63 pancreatic ovarian 62 prostate cancers 62 gastrointestinal cancers 62 soft tissue sarcomas 62 neoplastic lesions 62 atypical hyperplasia 62 thyroid nodules 62 cervical carcinoma 62 follicular thyroid cancer 62 colorectal cancer CRC 62 lesions 62 malignant growths 62 contralateral breast 62 nonmelanoma skin cancers 62 adenomatous 62 immunohistochemical staining 62 neurofibromas 62 sarcomatoid 62 invasive ductal 62 carcinoid 62 nodal metastases 62 CIN2 62 brain metastases 62 lung cancers 62 leiomyosarcoma 62 metastasis 62 malignant neoplasms 61 pancreatic prostate 61 malignant tumors 61 basal cell carcinomas 61 Carcinoma 61 renal cell carcinoma 61 malignant prostate 61 thyroid cancers 61 metastatic tumors 61 breast cancers 61 neck squamous cell 61 cystic lesions 61 situ CIS 61 hepatocellular carcinoma 61 esophageal cancers 61 leiomyoma 61 basal cell carcinoma BCC 61 papillary thyroid carcinoma 61 micrometastases 61 astrocytoma 61 pituitary adenomas 61 submucosa 61 breast lesions 61 epithelioid 61 cervical dysplasia 61 medullary thyroid cancer 61 nasopharyngeal carcinoma 61 colon cancers 61 castration resistant 61 lymph node involvement 61 gastric cancer 61 malignant lymphoma 61 EpCAM 61 neuroblastomas 61 resectable 61 HNSCC 61 hamartoma 61 hepatocellular carcinomas 61 malignant pleural mesothelioma 61 histological subtype 61 seminomas 61 serous ovarian cancer 61 thymoma 61 metastatic relapsed 61 nodal metastasis 61 colorectal cancers 61 oropharyngeal cancer 61 premalignant lesions 60 nasopharyngeal cancer 60 colorectal adenocarcinoma 60 ductal 60 myeloproliferative diseases 60 locoregional 60 liver metastases 60 histologic subtype 60 hyperplasia 60 epithelial ovarian 60 adenoma 60 schwannomas 60 thromboembolic events 60 hypoplasia 60 ovarian tumors 60 prostate breast 60 FDG uptake 60 HER2 positive 60 neuroendocrine cancers 60 malignant fibrous histiocytoma 60 prostate adenocarcinoma 60 rectal cancers 60 papillomas 60 ovarian cancers 60 solid tumors 60 cutaneous melanoma 60 nonmetastatic 60 GBM tumors 60 lymphoma subtypes 60 gastric carcinoma 60 hematologic toxicity 60 pancreatic lung 60 operable breast cancer 60 renal carcinoma 60 axillary lymph node dissection 60 squamous cell cancers 60 Gliomas 60 gliomas 60 histologic 60 neuroendocrine carcinoma 60 endometrial carcinoma 60 carcinoid tumors 60 squamous cell cancer 60 sonographic findings 60 uterine cancers 60 lymphadenopathy 60 metastatic cancer 60 locoregional recurrence 60 histopathologic 60 cytokeratin 60 liver metastasis 60 fallopian tube carcinoma 60 glioblastoma multiforme GBM 60 lobular carcinomas 60 invasive ductal carcinoma 60 nodular 60 HGPIN 60 histologies 60 metachronous 60 Hurthle cell 60 mRNA expression 60 ADPKD 60 ALCL 60 xenograft models 60 carcinoids 60 NSCLC 59 testicular tumors 59 EGFR mutation 59 Papillary 59 invasive carcinomas 59 CIN2 + 59 basal cell 59 myelofibrosis polycythemia vera 59 colorectal tumors 59 cutaneous squamous cell carcinoma 59 proto oncogene 59 lymph node 59 breast pancreatic 59 Uterine fibroids 59 endometrioid 59 hepatocellular cancer 59 myeloproliferative neoplasms 59 intraepithelial neoplasia 59 progesterone receptor negative 59 lung tumors 59 adenomas 59 grade gliomas 59 thyroid carcinoma 59 bladder tumors 59 lymphadenectomy 59 SPINK1 59 tumor recurrence 59 Sjögren syndrome 59 estrogen receptor ER 59 endometrial hyperplasia 59 esophageal squamous cell carcinoma 59 node metastases 59 superficial bladder cancer 59 lymphovascular invasion 59 Glioblastomas 59 breast tumors 59 Histologically 59 lymphocytosis 59 fallopian tube cancers 59 pheochromocytomas 59 testicular cancers 59 Proxinium TM 59 neoadjuvant therapy 59 explants 59 proximal colon 59 Squamous 59 ovarian lung 59 HER2 positive tumors 59 colorectal neoplasms 59 lung nodules 59 lymphocytic 59 chemoradiotherapy 59 pT2 59 histologic subtypes 59 lung adenocarcinomas 59 metastatic melanomas 59 cancerous enlargement 59 prostate cancer PCa 59 CIN3 59 PNET 59 esophageal carcinoma 59 oligodendrogliomas 59 prostate pancreatic 59 radiographic findings 59 hematologic malignancies 59 NMIBC 59 sarcoma 59 paraganglioma 59 HPV# 59 urothelial cancer 59 lymphopenia 59 epithelia 59 metastatic lymph nodes 59 HER2 negative 59 cytoreductive surgery 59 ductal carcinomas 59 prognostic factor 59 eccrine 59 metastatic RCC 59 bone metastasis 58 papillary carcinoma 58 lymphoid 58 desmoplastic 58 essential thrombocythemia 58 lymphoid cells 58 biochemical recurrence 58 recurrent NSCLC 58 neoplastic cells 58 T1a 58 lymphatic tissue 58 fibroma 58 Adenocarcinoma 58 myeloproliferative disorder 58 GBMs 58 DLBCL 58 BRCA1 mutation carriers 58 lobular cancer 58 androgen receptor AR 58 ALK mutations 58 pCR 58 epithelial cell 58 malignant neoplasm 58 ovarian breast 58 cervical intraepithelial neoplasia 58 benign lesions 58 pancreatic colon 58 colorectal gastric 58 extracranial 58 WT1 58 normal karyotype 58 calculi 58 histologic examination 58 hepatic metastases 58 adenomatous polyp 58 chromophobe 58 bowel cancers 58 urothelial 58 cytologically confirmed 58 transurethral resection 58 glioblastoma 58 resected 58 gastrointestinal stromal tumor 58 differentiated thyroid 58 cell lymphomas 58 metastatic malignant melanoma 58 Squamous Cell Carcinoma 58 metastatic carcinoma 58 lobular 58 lipomas 58 pathologic 58 benign neoplasms 58 radical nephrectomy 58 EGFr 58 cytogenetic abnormalities 58 colorectal pancreatic 58 ductal cancer 58 EGFR mutations 58 renal pelvis 58 metastatic cancers 58 nonsmall cell lung cancer 58 anal cancers 58 carcinoma HCC 58 immunoreactivity 58 Toxicities 58 osteochondroma 58 non metastatic osteosarcoma 58 cystectomy 58 glomerulonephritis 58 Basal cell 58 fibroadenomas 58 benign growths 58 xenografts 58 EGFRvIII 58 advanced adenoma 58 hormone receptor positive 58 metastatic colorectal 58 malignant gliomas 58 proctitis 58 HER2 positive cancers 57 castration resistant prostate cancer 57 bone metastases 57 unresectable 57 pre cancerous lesion 57 subependymal giant cell 57 metaplasia 57 Immunohistochemical staining 57 platinum refractory 57 small lymphocytic lymphoma 57 bronchogenic carcinoma 57 axilla 57 cell lymphoma ALCL 57 pancreatic carcinoma 57 EGFR inhibitors 57 adrenocortical cancer 57 basal cell cancer 57 castrate resistant 57 ductal lobular 57 extracapsular extension 57 EGFR 57 dysplasia 57 histologic findings 57 preoperative chemotherapy 57 prostate carcinomas 57 seminoma 57 malignant lymphomas 57 colorectal polyp 57 B7 H3 57 ALND 57 chemoradiation 57 penile cancers 57 HER2 + 57 metastatic bladder 57 trans retinoic acid 57 SCCHN 57 prostate lung 57 medically inoperable 57 parenchymal 57 medulloblastomas 57 toxicities 57 ERBB2 57 leukemia AML 57 urine cytology 57 node metastasis 57 pleural effusion 57 ependymomas 57 atherosclerotic lesions 57 acute leukemias 57 FLT3 57 immunocompetent 57 BRAF mutation 57 MGUS 57 p# mutations 57 supratentorial 57 axillary 57 ductal adenocarcinoma 57 gastrointestinal stromal tumors 57 pre cancerous lesions 57 hydronephrosis 57 nodular melanoma 57 Metastatic breast cancer 57 tumor xenograft models 57 Renal cell carcinoma 57 poorer prognosis 57 oesophageal 57 malignant nodules 57 surgical excision 57 colorectal carcinomas 57 SLNB 57 completely resected 57 atypia 57 Recurrences 57 polypoid 57 Immunohistochemical analysis 57 malignant transformation 57 HER2 receptor 57 ASCUS 57 ErbB2 57 hepatoma 57 ascites 57 follicular lymphoma 57 factor receptor EGFR 57 occult metastases 57 melanocytic nevi 57 lung adenocarcinoma 57 Adenomas 57 CYT# potent vascular disrupting 57 prognostic factors 57 invasive bladder 57 liposarcoma 57 basal cell cancers 57 EUS FNA 57 fibroadenoma 57 HbF 57 BRCA1 mutations 56 ErbB2 positive 56 esophagogastric junction 56 osteoid 56 histological subtypes 56 hypopharynx 56 seminal vesicle invasion 56 metastatic malignant 56 immunohistochemical 56 NF1 56 SUVmax 56 cystic 56 HBeAg negative 56 hilar 56 FGFR2 56 5FU 56 Adjuvant chemotherapy 56 HER2 overexpression 56 HER2 expression 56 solar keratosis 56 PC3 cells 56 nevi 56 lymph node removal 56 stenoses 56 intravesical therapy 56 splenic 56 Squamous cell carcinomas 56 overexpressed 56 N cadherin 56 tumor xenografts 56 polyposis 56 germline mutations 56 intraductal 56 TIMP 56 KIT mutations 56 breast cancer subtypes 56 thyrotoxicosis 56 basal cell skin 56 anterior uveitis 56 histopathologic examination 56 lymph nodes 56 thyroid nodule 56 recurrent squamous cell carcinoma 56 acute myeloid 56 CD4 + CD# 56 metastatic renal cell carcinoma 56 tumors GIST 56 TACE 56 thyroid carcinomas 56 adjuvant therapy 56 TNFalpha 56 pancreatic endocrine 56 CagA 56 pulmonary nodules 56 pericardial effusion 56 glioblastomas 56 squamous cell lung cancer 56 activating mutations 56 inguinal 56 extranodal 56 mutational status 56 pre cancerous 56 localized renal 56 Anaplastic 56 biliary tract cancer 56 hypopituitarism 56 superficial basal cell carcinoma 56 Histological examination 56 sentinel lymph nodes 56 FDG PET 56 syngeneic 56 cholelithiasis 56 mediastinal 56 V#F mutation 56 teratoma 56 stage IIIB 56 precancers 56 recurrent glioblastoma multiforme 56 tumor histology 56 precancerous lesion 56 serum prostate 56 parenchyma 56 lung colon 56 atrophic gastritis 56 chemotherapeutic agents 56 ductal breast cancer 56 CaP 56 metastatic prostate cancer 56 squamous carcinoma 56 NSCLC tumors 56 K ras mutations 56 mammographically 56 malignant melanomas 56 breast ovarian 56 peritoneal cancer 56 dysplastic 56 BRCA mutations 56 Gleevec resistant 56 neoadjuvant 56 pulmonary metastasis 56 radiochemotherapy 56 metastatic tumor 56 KRAS mutations occur 56 EGFR mutant 56 prognostic variables 56 carotid stenosis 56 mesothelial cells 56 CTEPH 56 mediastinum 56 xenograft tumors 56 ovarian pancreatic 56 chronic eosinophilic leukemia 56 pleural mesothelioma 56 pancreatic NET 56 contralateral breast cancer 56 hypermethylation 56 Helicobacter pylori infection 56 retroperitoneal 56 BCCs 56 metastatic basal cell 56 endometrial 56 hyperoxaluria 56 BRAF V#E 56 fine needle aspiration 56 Squamous cell 56 recurrent ovarian cancer 56 sclerosing 56 lung prostate 56 immunostaining 56 overexpression 56 peritoneal carcinomatosis 56 EBRT 56 LHRH receptor positive 56 bleomycin 56 myeloid 56 hypoechoic 56 osteochondromas 56 parotid 56 intracranial tumors 56 PSADT 56 malignant ovarian 56 sonographically 56 cutaneous lesions 56 underwent resection 56 unknown etiology 56 recurrent metastatic 56 infiltrative 56 lung metastasis 56 Metastases 56 progesterone receptor PR 55 activated lymphocytes 55 TTR gene 55 precancerous lesions 55 FluCAM arm 55 myeloproliferative disorders 55 metastatic melanoma 55 morphologic 55 wedge resection 55 metastatic GIST 55 Basal cell carcinoma 55 MAPK pathway 55 hormone receptor negative 55 prostatic 55 cancerous lesions 55 melanomas 55 antitumour activity 55 HER2 amplification 55 cutaneous T cell 55 Tumours 55 HER2 positive metastatic breast 55 chemoembolization 55 neurologic complications 55 mycophenolate mofetil 55 prognostic indicator 55 Li Fraumeni Syndrome 55 occlusive disease 55 cytotoxicity 55 molecular subtypes 55 clinicopathological features 55 IV NSCLC 55 BCG refractory 55 basal cell carcinoma 55 leukaemias 55 tumor necrosis 55 colorectal 55 INCB# [003] 55 PC# cells 55 metastatic prostate 55 axillary nodes 55 cancer mCRC 55 GIST tumors 55 hypervascular 55 oncoproteins 55 chronic periodontitis 55 Her2 55 estrogen receptor negative 55 vulvar intraepithelial neoplasia 55 aplasia 55 malignant lesion 55 transgene expression 55 benign moles 55 Surgical resection 55 GIST 55 mesenteric 55 Glioblastoma multiforme GBM 55 CD#c 55 cholangiocarcinoma 55 gastrointestinal stromal tumors GIST 55 antitumor effect 55 metastatic lung cancer 55 osteoid osteoma 55 cytoreduction 55 adrenalectomy 55 mutant p# 55 nephrectomy 55 c MYC 55 synovial sarcoma 55 Leydig cell 55 vimentin 55 angiosarcoma 55 perianal 55 pancreatic islet cell 55 KRAS mutations 55 anti angiogenic therapy 55 promoter methylation 55 lymphoproliferative disorders 55 androgen independent 55 neurofibroma 55 echogenic 55 mycosis fungoides 55 anaplastic astrocytoma AA 55 neoadjuvant chemotherapy 55 ischemic lesions 55 unresectable tumors 55 endocrine tumors 55 bacteriuria 55 adjuvant radiotherapy 55 ccRCC 55 lobular breast cancer 55 isoform 55 LSIL 55 chemoradiation therapy 55 pleura 55 nevus 55 metastatic pancreatic 55 luminal 55 chronic prostatitis 55 Irinotecan 55 metastatic gastric 55 biopsy specimens 55 TMPRSS2 ERG 55 oncogenic transformation 55 CIN3 + 55 histopathological 55 choriocarcinoma 55 metastatic neuroendocrine tumors 55 metastatic adenocarcinoma 55 varices 55 liver colon rectal 55 congenital anomalies 55 oropharyngeal 55 benign nodules 55 esophageal gastric 55 endometrial adenocarcinoma 55 cisplatin resistant 55 colorectal lung 55 myelodysplastic syndrome MDS 55 hyperplastic polyps 55 epithelial ovarian cancer 55 pilocytic astrocytomas 55 histologically confirmed 55 prostate cancer AIPC 55 T#I [002] 55 basal cell nevus syndrome 55 peritumoral 55 mesothelin 55 lung colorectal 55 sentinel node 55 rebleeding 55 cell lymphoma CTCL 55 osteoblastic 55 ER alpha 55 heavily pretreated 55 atypical ductal hyperplasia 55 MGd 55 EGF receptor 55 ovarian carcinomas 55 precancerous cervical lesions 55 hyperintense lesions 55 ovarian colorectal 55 endoscopic ultrasonography 55 chemoresistant 55 BRAF mutations 55 BRCA deficient 55 pancreatic bladder 55 p# biomarker 55 castrate resistant prostate cancer 55 imatinib Gleevec 55 tunica vaginalis 55 axillary lymph node 55 cellularity 55 B Cell Lymphoma 55 grade glioma 55 Melanomas 55 acute myelogenous leukemia AML 55 grade squamous intraepithelial 55 lichen planus 55 miRNA expression 55 karyotypes 55 Activating mutations 55 TGF β 55 micrometastasis 55 liver histology 55 receptor subtype 55 Figure 2C 55 ertapenem 55 malignant cancerous 55 clinicopathologic 55 ELOXATIN 55 catheter angiography 55 alveolar epithelial cells 55 inducible nitric oxide synthase 55 total thyroidectomy 55 oligodendroglioma 55 leukemia ALL 55 resection 55 hypercalcemia 55 systemic scleroderma 55 proliferative diabetic retinopathy 55 familial amyloidotic polyneuropathy FAP 55 pre malignant lesions 55 Immunohistochemistry 55 postoperative chemotherapy 55 Computed tomography 55 molecular abnormalities 55 hypophosphatemia 55 submandibular gland 55 melanoma 55 prostate TURP 55 Sezary syndrome 55 extramedullary 55 gastrectomy 55 sulfasalazine 54 advanced hepatocellular carcinoma 54 inflammatory lesions 54 fibrotic disease 54 peripheral blood mononuclear 54 Radical prostatectomy 54 HBeAg positive 54 GNAQ 54 prostate cancer CRPC 54 taxane therapy 54 IGFBP 3 54 prognostic significance 54 microvascular complications 54 antiangiogenic therapy 54 sentinel nodes 54 relapsed SCLC 54 luteinizing hormone releasing 54 Leukemias 54 core needle biopsy 54 HDACi 54 precancer 54 Medullary thyroid cancer 54 hypoperfusion 54 herpesviruses 54 CLL cells 54 osteolytic 54 pathologic diagnosis 54 necrotizing 54 primitive neuroectodermal tumor 54 leukemia CLL 54 cTnT 54 TRAIL R1 54 macules 54 IGF 1R 54 papillary thyroid cancer 54 mitomycin C 54 metastatic lesion 54 subcutaneous tissue 54 hyperechoic 54 sentinel lymph node biopsy 54 extrahepatic 54 subtypes 54 gene polymorphisms 54 esophageal tumors 54 cervical lymph node 54 metastatic colorectal cancer 54 genitourinary tract 54 microbleeds 54 sonographic appearance 54 HER2/neu 54 genital tract infections 54 colorectal adenomas 54 cell adhesion molecule 54 intestinal polyps 54 oncoprotein 54 cytological 54 tumor subtypes 54 ipsilateral 54 axillary dissection 54 thyroglobulin 54 androgenetic alopecia 54 micronuclei 54 TP# mutations 54 eosinophilic 54 BRAF V#E mutation 54 varicocele 54 receptor tyrosine kinase inhibitor 54 breast endometrial 54 neurological manifestations 54 colon carcinoma 54 hyperbilirubinemia 54 PI3K Akt 54 androgen deprivation 54 Kaposi sarcoma 54 basal cells 54 malignant polyps 54 solar keratoses 54 karyotype 54 urothelial bladder cancer 54 intraoperative complications 54 nasopharyngeal carcinoma NPC 54 thoracoscopic lobectomy 54 subclinical hypothyroidism 54 MAGE A3 54 nonmelanoma skin cancer 54 pT3 54 vulvar cancer 54 granulomas 54 polypoid lesions 54 papilloma 54 antitumor activity 54 ABCB1 54 heterotopic ossification 54 PCNSL 54 dysplastic lesions 54 immunohistochemical analysis 54 biliary strictures 54 imatinib resistant 54 lymphoid malignancies 54 ependymoma 54 febrile neutropenia 54 testis 54 Candida infection 54 malignant pleural mesothelioma MPM 54 Malignant mesothelioma 54 specific antigen PSA 54 bladder carcinoma 54 cystic lesion 54 lymphangiogenesis 54 estrogen receptor 54 MLL AF9 54 radical prostatectomy RP 54 activating mutation 54 Vicinium TM 54 dysplastic nevi 54 contralateral 54 lymphocytic leukemia 54 aneuploidies 54 tumorigenicity 54 VUR 54 scintigraphic 54 trophoblasts 54 CTGF 54 synovial 54 Glioma 54 medulloblastoma 54 pDC 54 tonsillar 54 Malignant Melanoma 54 EGFR tyrosine kinase inhibitors 54 CMV infection 54 HER-2/neu 54 pelvic lymph nodes 54 parathyroid carcinoma 54 HLA DR 54 relapsed ovarian cancer 54 endometrial ovarian 54 noncancerous cells 54 non squamous NSCLC 54 fibrocystic changes 54 intraepithelial 54 Foxp3 54 myometrium 54 CD# + [001] 54 Trichophyton rubrum 54 monoclonal gammopathy 54 candidemia 54 pleural 54 c MET 54 stromal 54 precancerous cervical 54 bone scintigraphy 54 EGFR HER2 54 ara C 54 generalized seizures 54 oropharynx 54 alkaline phosphatase 54 testicular germ cell 54 miR #a [001] 54 situs inversus 54 idiopathic myelofibrosis 54 CLL SLL 54 estrogen receptor progesterone receptor 54 FGFR3 54 colorectal liver metastases 54 ERK1 2 54 neoplasia CIN 54 nasopharynx 54 Hepatocellular Carcinoma HCC 54 duodenal 54 supraclavicular 54 ectopic 54 KRAS mutation 54 Carcinoid tumors 54 tumor 54 activin

Back to home page